This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
New research has uncovered a surprising culprit underlying cardiovasculardiseases in obesity and diabetes -- not the presence of certain fats, but their suppression. Ironically, the findings could ultimately lead to therapies that maintain high levels of these protective lipids in patients with obesity.
Babies born to pregnant women with obesity are more likely to develop heart problems and diabetes as adults due to fetal damage caused by the high-fat, high-energy diet of their mother.
Background Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovasculardisease. In addition, we investigated the beneficial effects of fenofibrate on HF hospitalization. During the 4.22-year
Cardiovasculardisease represents a significant risk factor for mortality in individuals with type 2 diabetes mellitus (T2DM). High-density lipoprotein (HDL) is believed to play a crucial role in maintaining c.
This new insight into the flow of fats through the body points to new therapeutic targets for mitigating diseases like ASCVD, non-alcoholic fatty liver disease, obesity, diabetes, peripheral neuropathy, and neurodegeneration.
With Medicare now covering semaglutide for people with obesity and cardiovasculardisease who don't have diabetes, a study looks at who that might include, depending on what cutoffs prescription plans apply.
In today’s society, the prevalence of obesity has become a significant concern. have obesity, and this rate has increased by more than 10 percentage points in the past two decades. Understanding the prevalence of obesity is crucial in comprehending why events like Healthy Weight Week are essential. of adults in the U.S.
The five classic risk factors for cardiovasculardisease are well knownsmoking, high blood pressure, high cholesterol, diabetes, and underweight or overweight/obesity. All increase the likelihood of heart ailments down the road.
Obesity is a multifaceted disease that is directly and indirectly implicated in atherosclerotic cardiovasculardisease (CVD), heart failure (HF), atrial fibrillation (AF), and multiple CVD risk factors, including dyslipidemia, hypertension, type 2 diabetes mellitus (DM), and sleep disorders.
Driven by common pathophysiologic underpinnings (eg, inflammation and neurohormonal dysregulation), cardiovasculardisease, cognitive impairment, and frailty also share the following risk factors: hypertension, diabetes, obesity, sedentary behavior, and tobacco use.
A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8 population could be affected by cardiovasculardisease within the next 30 years, according to two new science reports. and Susan F. of the population.
A new JAMA study revealed that a shocking 90% of US adults are at risk of developing cardiovascular-kidney-metabolic (CKM) syndrome, underscoring the need for preventative action before we face a wave of CKM-related heart disease. Stage 4 (heart disease, with or without kidney disease) – 9.2% in Whites).
years; p < 0.001), had more cardiovascular risk factors, target organ damage and cardiovasculardisease (CVD) in comparison with those without hypertension. These patients were older (65.8 ± 10.9 vs. 51.6 ± 14.7 Conclusions About half of patients attended in primary care settings have hypertension in Spain.
We projected through 2050, overall and by age and race and ethnicity, accounting for changes in disease prevalence and demographics.RESULTS:We estimate that among adults, prevalence of hypertension will increase from 51.2% Diabetes (16.3% to 26.8%) and obesity (43.1% Prevalences of coronary disease (7.8% in 2020 to 61.0%
When it comes to cardiovasculardisease, two of the biggest risk factors we must consider are: ApoB concentration - A measure of the number of circulating lipid particles. Trends in the number of obese and severely obese people by region. Relationship of BMI and Risk Of Diabetes. But only moderately.
For overweight or obese individuals without diabetes, but with pre-existing cardiovasculardisease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows. However, with price reductions or rebates up to 50%, it could meet the benchmark for value in health care.
Semaglutide reduces cardiovascular events, regardless of baseline glycated hemoglobin (HbA1c), among people with overweight or obesity and established atherosclerotic cardiovasculardisease, according to a study published online June 22 in Diabetes Care.
Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes. Multiple logistic regression analysis was used to evaluate the impact of heart failure on the risk of pre-eclampsia, with adjustment for established risk factors and other cardiovasculardiseases.
In a trial in patients with cardiovasculardisease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8
Obesity has increased in recent years with consequences on diabetes and other comorbidities. Thus, 1 out of 3 diabetic patients suffers cardiovasculardisease (CVD). The network among glucose, immune system, e.
Pregnancy complications such as preeclampsia and gestational diabetes have recently been associated with a higher risk of developing heart disease later in life. But a new study has found obesity before or during pregnancy is the actual root cause of future cardiovasculardisease. “We
Don’t worry—you can still access the 19th Annual CMHC sessions through our On-Demand platform, which offers 14 CME credits across four comprehensive tracks: Cardiorenal Health: Stay up-to-date with the latest on therapies for resistant hypertension, chronic kidney disease markers, and cardiac risk assessment tools.
Ballantyne, MD , emphasized that while fellows may consider prevention “boring,” it is crucial for avoiding resource-intensive late-stage cardiovasculardisease (CVD). He highlighted that cardiovascular health is essential for cognitive health, noting the common occurrence of vascular dementia.
Less than two weeks after Novo Nordisk’s weight-loss drug Wegovy gained expanded FDA approval for cardiovascular event risk reduction, CMS issued a new Medicare Part D guidance that allows coverage of obesity drugs for senior patients with “an additional medically accepted indication”… like cardiovasculardisease.
Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovasculardisease, and chronic kidney disease. The robust conference agenda begins with FDA updates and advancements in cardiorenal metabolic care.
Aims:Asian Americans experience disproportionate burdens of cardiovascular risk factors and cardiovasculardisease (CVD). However, the trends in cardiovascular risks in adults from different Asian ethnic backgrounds remain understudied. Asian Indian adults exhibited uptrends in overweight/obesity (AAPC: 1.1%,p<
As a leader in the field of research-based cardiometabolic health education, CMHC is proud to present its CME education outcomes study at ADA (American Diabetes Association) 2024 Scientific Sessions, which offers its education-focused agenda to a wide number of healthcare practitioners from all areas of the U.S.
What is the value of the new American Heart Association’s (AHA’s) PREVENT equation(s) for primary prevention that use routinely available clinical variables including obesity, diabetes, kidney disease, and social risk for predicting 10- and 30-year absolute risk of cardiovasculardisease (CVD) including each atherosclerotic CVD (ASCVD) and heart (..)
Meanwhile, the risk of suffering from cardiovasculardisease (CVD) has been increasing with ageing. Cancer, atrial fibrillation (AF) and coronary artery disease share some common factors and interact with each other, such as obesity, aging, diabetes, and inflammation, but the potential specific mechanism is still unclear.
Semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovasculardisease who do not have diabetes, according to new research. of their body weight and experienced improvements in other risk factors for cardiovasculardisease.
Cardiomyopathy, a heterogeneous pathological condition characterized by changes in cardiac structure or function, represents a significant risk factor for the prevalence and mortality of cardiovasculardisease (CVD). Research conducted over the years has led to the modification of definition and classification of cardiomyopathy.
Circadian rhythms in blood pressure and heart rate, among other functions, are crucial for cardiovascular health and preventing cardiovasculardisease. This is supported by studies showing that ALAN exposure is associated with a range of conditions like cardiometabolic disease, obesity, and diabetes.
There is a clear relationship between sleep deprivation and the development of conditions like obesity, diabetes, and hypertension. Impaired glucose tolerance : After just one week of sleep deprivation, insulin sensitivity decreases, pushing patients toward diabetes.
Insulin resistance is a significant driver of cardiovascular risk. Insulin resistance is a precursor condition to metabolic syndrome and type 2 diabetes, both major drivers of heart disease. Obesity is one of the biggest global health concerns we face today. Obesity is also a key driver of risk for cardiovasculardisease.
Background Implementation of the cardiovasculardisease (CVD) prevention guidelines in the UK has been repeatedly evaluated under the auspices of the British Cardiovascular Society in three Action on Secondary and Primary Prevention by Intervention to Reduce Events (ASPIRE) surveys in 1994–1995, 2008–2010 and 2017–2019.
The consumption of ultraprocessed foods is increasing worldwide, and damning evidence implicates these “foods” in the diseases of civilization — type 2 diabetes, obesity, and cardiovasculardisease. How might UPF elevate one’s risk for cardiometabolic disease?
The throng of epidemiological evidence hasn’t helped either — one week “butter is back” and the next, red meat is giving us diabetes. These gene-nutrient interactions influence things like the microbiome and gene expression, thereby influencing our risk for diseases like obesity, diabetes, and cardiovasculardisease.
BackgroundIn 2023, the American Heart Association defined the concept of cardiovascularkidneymetabolic (CKM) syndrome as a health disorder ascribed to connections among obesity, diabetes, chronic kidney disease, and cardiovasculardisease. CKM syndrome stages 3 and 4 are considered advanced.
Changes in BCAA homeostasis have emerged as pivotal contributors in the pathophysiology of several cardiometabolic diseases, including type 2 diabetes, obesity, hypertension, atherosclerotic cardiovasculardisease, and heart failure.
Themed “Decoding the Constellation of Cardiometabolic Health and Risk Factors,” this year’s congress will tackle the growing health threat posed by cardiometabolic diseases, affecting 47 million people in the US. Singh, MBBS, FRCP, MBA Advances in Obesity Pharmacotherapy Louis J. When I heard of his passing, I felt quite sad.
For instance, a pediatric provider may be only interested in topics pertaining to childhood obesity. They could find resources and education focused on that condition within both the Obesity Management and Pediatrics hubs.
BackgroundAsian people in the United States have different sociodemographic and health‐related characteristics that might affect cardiovasculardisease (CVD) risk by ethnicity and birthplace. Journal of the American Heart Association, Ahead of Print. However, they are often studied as a monolithic group in health care research.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content